Kalium Health aims to make it quicker and easier for patients to monitor and manage unstable blood electrolyte levels that can become life-threatening, especially for those with kidney disease. Its first product is a handheld test device for monitoring blood potassium level with clinical accuracy.
The University of Cambridge spin-out is developing the device in response to patients’ request for an alternative to current methods, which involve hospital-based tests requiring a venous blood sample. These are often considered inconvenient, expensive and can lead to delays with treatment. In contrast, Kalium’s device will provide users with real-time results in any setting.
Tom Collings, CEO, is responsible for setting the company’s overall strategy and overseeing operational activities. Supported by the SME Leaders Programme, Tom aims to gain skills in areas such as recruitment, effective leadership and financial management to build a motivated team and drive efficiency as Kalium’s operations rapidly expand. Networking with peers and support from a mentor will help Tom as he seeks to raise the company’s profile and develop the right commercial partnerships to help Kalium towards its goal to launch its first device in Europe and the US in the next five years.
